The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a change to the license of the Comirnaty Omicron XBB.1.5 30 micrograms/dose (single-dose vials) after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
Duke-NUS scientist awarded major funding to develop therapeutics for chronic inflammation
Associate Professor Lena Ho from Duke-NUS Medical School has been awarded US$1.85 million (approx. S$2.51 million) to further her team’s research in developing microproteins into